AU2020325054A1 - Hybrid amphotericin b derivatives with reduced toxicity - Google Patents

Hybrid amphotericin b derivatives with reduced toxicity Download PDF

Info

Publication number
AU2020325054A1
AU2020325054A1 AU2020325054A AU2020325054A AU2020325054A1 AU 2020325054 A1 AU2020325054 A1 AU 2020325054A1 AU 2020325054 A AU2020325054 A AU 2020325054A AU 2020325054 A AU2020325054 A AU 2020325054A AU 2020325054 A1 AU2020325054 A1 AU 2020325054A1
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
alkyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020325054A
Other languages
English (en)
Inventor
Martin D. Burke
Arun Maji
Jiabao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois at Urbana Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana Champaign, University of Illinois System filed Critical University of Illinois at Urbana Champaign
Publication of AU2020325054A1 publication Critical patent/AU2020325054A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020325054A 2019-08-08 2020-08-07 Hybrid amphotericin b derivatives with reduced toxicity Abandoned AU2020325054A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962884471P 2019-08-08 2019-08-08
US62/884,471 2019-08-08
US201962927731P 2019-10-30 2019-10-30
US62/927,731 2019-10-30
PCT/US2020/045399 WO2021026450A1 (en) 2019-08-08 2020-08-07 Hybrid amphotericin b derivatives with reduced toxicity

Publications (1)

Publication Number Publication Date
AU2020325054A1 true AU2020325054A1 (en) 2022-03-03

Family

ID=74503744

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020325054A Abandoned AU2020325054A1 (en) 2019-08-08 2020-08-07 Hybrid amphotericin b derivatives with reduced toxicity

Country Status (9)

Country Link
US (1) US20230000891A1 (https=)
EP (1) EP4009984A4 (https=)
JP (1) JP2022543421A (https=)
KR (1) KR20220058547A (https=)
CN (1) CN114502173A (https=)
AU (1) AU2020325054A1 (https=)
CA (1) CA3149819A1 (https=)
IL (1) IL290290A (https=)
WO (1) WO2021026450A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431874A1 (en) * 1989-12-08 1991-06-12 Beecham Group p.l.c. Novel compounds
US5981721A (en) * 1997-10-23 1999-11-09 Karykion Corporation Polyene macrolide schiff bases, their alkyl esters and processes for preparing polyene macrolide alkyl ester salts thereof
KR102548341B1 (ko) * 2013-10-07 2023-06-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 개선된 치료 지수를 갖는 암포테리신 b 유도체
ES2749927T3 (es) * 2014-05-16 2020-03-24 Univ Illinois Derivado de anfotericina b con toxicidad reducida
WO2016014779A1 (en) * 2014-07-23 2016-01-28 The Board Of Trustees Of The University Of Illinois Antifungal polyene macrolide derivatives with reduced mammalian toxicity
WO2016061437A1 (en) * 2014-10-17 2016-04-21 The Board Of Trustees Of The University Of Illinois Scalable synthesis of reduced toxicity derivative of amphotericin b
WO2016112260A1 (en) * 2015-01-08 2016-07-14 The Board Of Trustees Of The University Of Illinois Concise synthesis of urea derivatives of amphotericin b
JP7240811B2 (ja) * 2015-04-15 2023-03-16 スファンガ セラピューティクス インコーポレイテッド アムホテリシンｂの誘導体
CA3111565A1 (en) * 2018-09-07 2020-03-12 The Board Of Trustees Of The University Of Illinois Hybrid amphotericin b derivatives with reduced toxicity

Also Published As

Publication number Publication date
CN114502173A (zh) 2022-05-13
CA3149819A1 (en) 2021-02-11
EP4009984A4 (en) 2023-09-06
KR20220058547A (ko) 2022-05-09
WO2021026450A1 (en) 2021-02-11
IL290290A (en) 2022-04-01
US20230000891A1 (en) 2023-01-05
JP2022543421A (ja) 2022-10-12
EP4009984A1 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
JP7636004B2 (ja) アムホテリシンｂのハイブリッドアミド誘導体
EP3423446B1 (de) Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
AU2019279928B2 (en) Amphotericin B derivatives with improved therapeutic index
AU2019335409B2 (en) Hybrid amphotericin B derivatives with reduced toxicity
US20230000891A1 (en) Hybrid amphotericin b derivatives with reduced toxicity
US20250387422A1 (en) Formulation of an amphotericin b hybrid amide derivative in dsgpeg2k micelles
WO2020216669A1 (de) Phenylsubstituierte imidazopyridinamide und ihre verwendung
JP7656359B2 (ja) アムホテリシンｂのハイブリッドアミド誘導体

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application